clinical trial · NCT06042920
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
Bristol-Myers Squibb·phase4·terminated·n = 130
Palmoplantar PsoriasisGenital PsoriasisDeucravacitinibPlacebo
brief summary
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.
started
Oct 9, 2023
primary completion
Apr 25, 2025
completion
Apr 25, 2025
last updated
Apr 17, 2026
official title
A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Non-Pustular PalmoPlantar and Genital Psoriasis (Psoriatyk Special Sites)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol